<DOC>
	<DOCNO>NCT01485991</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy TMC435 combination peginterferon ( PegIFN ) + ribavirin ( RBV ) mean establish non- inferiority compare approve regimen telaprevir + PegIFN + RBV patient previously fail PegIFN .</brief_summary>
	<brief_title>TMC435HPC3001 - An Efficacy , Safety Tolerability Study TMC435 v Telaprevir Combination With PegINFα-2a Ribavirin Chronic Hepatitis C Patients Who Were Null Partial Responders Prior PegINFα-2a Ribavirin Therapy</brief_title>
	<detailed_description>This study randomize ( study drug assign chance like flip coin ) , double-blind ( neither physician patient know name assign drug ) , double-dummy ( patient receive active inactive pill also call placebo ) , 2-arm , multicenter Phase III clinical study adult treatment experience Chronic Hepatitis C ( CHC ) genotype-1 infected patient fail respond least 1 previous course PegINFα-2a/ RBV therapy . The purpose trial study efficacy TMC435 combination PegINFα-2a RBV 48 week treatment compare approve regimen telaprevir combination PegINFα-2a RBV 48 week treatment . The study consist screen period ( maximum 6 week ) , treatment period ( 48 week ) post-treatment period ( 72 week start treatment ) . For first 12 week one group patient take TMC435 TVR placebo , plus PegINFα-2a RBV . The group take TMC435 placebo TVR , plus PegINFα-2a RBV . After 12 week , patient arm take PegINFα-2a RBV week 48 . After patient stop take study medication , continue go doctor 's office study visit total 72 week start study treatment . Patients monitor safety throughout study . Study assessment study visit may include , limited : blood urine collection testing , electrocardiogram ( ECG ) assessment ( measurement electrical activity heart ) , patient questionnaire , physical examination .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patient must liver biopsy screening ( screen baseline visit ) , unless patient undergo procedure evidence portal hypertension associate cirrhosis . For patient liver biopsy perform 2 year prior screen without biopsy ( contraindication portal hypertension ) , noninvasive stag assessment need available . Noninvasive stag assessment include FibroScan , MRElastography , FibroTest/FibroSure must older 6 month prior screen Chronicity hepatitis C virus ( HCV ) infection , confirm one following : presence antiHCV antibody and/or HCV ribonucleic acid ( RNA ) least 6 month prior screen visit and/or presence fibrosis biopsy Genotype 1 HCV infection plasma HCV RNA &gt; 10,000 IU/mL ( confirm screen ) Patient must least 1 documented previous course treatment PegINFα2a PegINFα2b combination ribavirin ( RBV ) ( least 12 week null responder 20 week partial responder ) Hepatic decompensation ( impaired functioning liver ) , indicate significant laboratory abnormality active disease Infection Human Immunodeficiency Virus ( HIV ) non genotype 1 hepatitis C Liver disease relate hepatitis C infection Previous chronic hepatitis C treatment , PegIFN RBV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435HPC3001</keyword>
	<keyword>TMC435</keyword>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>HEP C</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Null responder</keyword>
	<keyword>Partial responder</keyword>
</DOC>